AT7519 HydrochlorideMulti-CDK inhibitor CAS# 902135-91-5 |
- LY2835219
Catalog No.:BCC1113
CAS No.:1231930-82-7
- AT7519 trifluoroacetate
Catalog No.:BCC1377
CAS No.:1431697-85-6
- Roscovitine (Seliciclib,CYC202)
Catalog No.:BCC1105
CAS No.:186692-46-6
- Nu 6027
Catalog No.:BCC1154
CAS No.:220036-08-8
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 902135-91-5 | SDF | Download SDF |
PubChem ID | 25033099 | Appearance | Powder |
Formula | C16H18Cl3N5O2 | M.Wt | 418.71 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 300 mg/mL (716.49 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide;hydrochloride | ||
SMILES | C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl.Cl | ||
Standard InChIKey | PAOFPNGYBWGKCO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H17Cl2N5O2.ClH/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9;/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.In Vitro:AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells[1]. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines[2]. AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels[3].In Vivo:AT7519 inhibits tumor growth in a human MM xenograft mouse model[1]. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice[2]. References: |
AT7519 Hydrochloride Dilution Calculator
AT7519 Hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3883 mL | 11.9414 mL | 23.8829 mL | 47.7658 mL | 59.7072 mL |
5 mM | 0.4777 mL | 2.3883 mL | 4.7766 mL | 9.5532 mL | 11.9414 mL |
10 mM | 0.2388 mL | 1.1941 mL | 2.3883 mL | 4.7766 mL | 5.9707 mL |
50 mM | 0.0478 mL | 0.2388 mL | 0.4777 mL | 0.9553 mL | 1.1941 mL |
100 mM | 0.0239 mL | 0.1194 mL | 0.2388 mL | 0.4777 mL | 0.5971 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: AT7519 showed potent antiproliferative activity (40-940 nmol/L) in a panel of human tumor cell lines.
Cyclin-dependent kinases (CDK) play a central role in the growth, division, and death of eukaryotic cell. This crucial role in cell cycle progression and their deregulation in several human cancers make them attractive therapeutic oncology targets. Series of CDK inhibitors was developed, among which, AT7519 is in early-phase clinical development currently.
In vitro: AT7519 showed potent antiproliferative activity (40-940 nmol/L)in a panel of human tumor cells, and the mechanism of action was shown to be consistent with the inhibition of CDK1 and CDK2. Cell cycle arrest caused by AT7519 followed by apoptosis in human tumor cells and inhibited tumor growth in human tumor xenograft models [1].
In vivo: Tumor regression was observed following twice daily dosing of AT7519 in the HCT116 and HT29 colon cancer xenograft models. The authors show that these effects are linked to inhibition of CDKs in vivo and that AT7519 induces tumor cell apoptosis [1].
Clinical trial: A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Electrocardiogram review suggested a dose-dependent increase in QTc and recruitment was discontinued without establishing a maximum tolerated dose. 4 patients with stable disease for >6 months and one had a prolonged partial response. Pharmacokinetic profile indicated modest interpatient variation with linear exposure at increased doses. AT7519 elicited clinical and PD activity resulting from CDK inhibition at doses below the appearance of DLT of QTc prolongation [2].
References:
[1] Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, Lyons JF, Thompson NT.Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009;8(2):324-32.
[2] Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol. 2011;22(9):2137-43.
- Gossypolone
Catalog No.:BCC1375
CAS No.:4547-72-2
- GSK 5959
Catalog No.:BCC5597
CAS No.:901245-65-6
- Fostamatinib (R788)
Catalog No.:BCC5082
CAS No.:901119-35-5
- TAME
Catalog No.:BCC4367
CAS No.:901-47-3
- Rebamipide
Catalog No.:BCC4836
CAS No.:90098-04-7
- AVX 13616
Catalog No.:BCC5407
CAS No.:900814-48-4
- Chondroitin sulfate
Catalog No.:BCN1312
CAS No.:9007-28-7
- 5-O-beta-D-Glucopyranosylmyricanol
Catalog No.:BCN8044
CAS No.:90052-02-1
- AS-252424
Catalog No.:BCC4988
CAS No.:900515-16-4
- PF-3274167
Catalog No.:BCC6451
CAS No.:900510-03-4
- Inulin
Catalog No.:BCC4789
CAS No.:9005-80-5
- Ylangenyl acetate
Catalog No.:BCN6704
CAS No.:90039-63-7
- NVP-LCQ195
Catalog No.:BCC1816
CAS No.:902156-99-4
- UBP 310
Catalog No.:BCC6052
CAS No.:902464-46-4
- FPA 124
Catalog No.:BCC7518
CAS No.:902779-59-3
- 10-Deacetyl-7-xylosyl paclitaxel
Catalog No.:BCN2947
CAS No.:90332-63-1
- 7-Xylosyl-10-deacetyltaxol B
Catalog No.:BCN7667
CAS No.:90332-64-2
- 7-Xylosyl-10-deacetyltaxol C
Catalog No.:BCN7663
CAS No.:90332-65-3
- 7-Xylosyltaxol
Catalog No.:BCN5341
CAS No.:90332-66-4
- Shizukolidol
Catalog No.:BCN4444
CAS No.:90332-92-6
- Seneciphyllinine
Catalog No.:BCN2132
CAS No.:90341-45-0
- 10-O-Coumaroyl-10-O-deacetylasperuloside
Catalog No.:BCN7614
CAS No.:903519-82-4
- 7-Xylosyltaxol B
Catalog No.:BCN7675
CAS No.:90352-19-5
- Bicalutamide
Catalog No.:BCC2481
CAS No.:90357-06-5